SoftBank Vision Fund makes 1st Japan investment with biotech firm
Aculys draws $59m as tech group diversifies portfolio beyond U.S. and China
SoftBank Group has been focusing more on smaller investments beyond the U.S. and China in its second Vision Fund. (Photo by Yoichi Iwata)
TOKYO -- SoftBank Group's Vision Fund has invested in a Japanese company for the first time, Nikkei has learned, as the tech investor accelerates a push for geographic diversity in its portfolio.
The Vision Fund led a 6.8 billion yen ($59.7 million) investment into Aculys Pharma, a biotech startup co-founded in January by Kazunari Tsunaba, the former president of the Japanese arm of Novartis.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30